Johnson and Johnson Recalls Blood Glucose Meters After Death (JNJ)
Healthcare product company, Johnson & Johnson (JNJ) issues recall on blood glucose meters following the death of a patient.
Following the death of a patient in Europe, JNJ is recalling 1.9 million of its blood glucose meters, including 90,000 in the U.S.
The company is recalling three of its models, which accounts for 1.9 million blood glucose meters in total, including the OneTouch VerioIQ which is sold in the U.S. These devices reportedly gave patients inaccurate reading or shut off when the patient had dangerously high blood sugar levels.
JNJ said that it had started to test this product last year after an internal company noticed that there may be a problem. The error was caused by a software problem.
Johnson & Johnson shares were mostly flat during premarket trading Tuesday. The stock has increased 23% in the past year.
The Bottom Line
Shares of Johnson & Johnson (JNJ) have a 3.06% yield, based on Monday’s closing price of $79.68.
Johnson & Johnson (JNJ) is a “Recommended” dividend stock at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability